Download MendeleyCovalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H.G., Lim, S.M., Manandhar, A., Gondi, S., Sim, T., Westover, K.D., Gray, N.S.(2017) ACS Med Chem Lett 8: 61-66
- PubMed: 28105276
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00373
- Primary Citation of Related Structures:
5KYK - PubMed Abstract:
Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure-activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate analogues such as compound 11 , which, despite exhibiting reduced efficiency as covalent G12C KRAS inhibitors, remove the liability of the hydrolytic instability of the diphosphate moiety present in SML-8-73-1 and provide the foundation for development of prodrugs to facilitate cellular uptake. The SAR and crystallographic results reaffirm the exquisite molecular recognition that exists in the diphosphate region of RAS for guanosine nucleotides which must be considered in the design of nucleotide-competitive inhibitors.
Organizational Affiliation:
Department of Cancer Biology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
